Related Experiment Videos
Atrial fibrillation: reducing stroke risk with low-dose anticoagulation
1College of Medicine, University of Arizona, Tucson.
Geriatrics
|May 1, 1994
Summary
Atrial fibrillation (AF) increases stroke risk, but oral anticoagulants like warfarin can safely prevent embolic strokes in patients with AF. A target INR of 2.0 to 3.0 is recommended for effective treatment with reduced bleeding risk.
Area of Science:
- Cardiology
- Neurology
- Geriatrics
Background:
- Atrial fibrillation (AF) is a major risk factor for systemic embolism, with incidence increasing significantly with age.
- AF commonly co-exists with hypertension, coronary heart disease, and congestive heart failure, compounding patient risk.
- The prevalence of AF in Americans over 75 reaches 12-16%.
Purpose of the Study:
- To review the efficacy and safety of oral anticoagulants in patients with atrial fibrillation.
- To outline current recommendations for anticoagulation therapy in AF patients.
Main Methods:
- Analysis of five clinical trials published since 1989 evaluating oral anticoagulants in AF patients.
- Review of recommendations from the American College of Chest Physicians (ACCP).
Main Results:
- Oral anticoagulants significantly and safely reduce the risk of embolic stroke in patients with AF.
- Long-term warfarin therapy is recommended for AF patients with cardiovascular disease, thyrotoxicosis, or age 60+.
- An INR range of 2.0 to 3.0 is effective and associated with less bleeding compared to high-intensity treatment.
Conclusions:
- Anticoagulation therapy is crucial for managing stroke risk in atrial fibrillation patients.
- Warfarin therapy within a specific INR range offers a favorable balance of efficacy and safety.
- These findings support current guidelines for AF management.